These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Neurological manifestations of postcovid syndrome]. Kamchatnov PR; Cheremin RA; Skipetrova LA; Chugunov AV Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(3):7-15. PubMed ID: 35394713 [TBL] [Abstract][Full Text] [Related]
3. Determination of the Prevalence of Postcovid Syndrome and Assessment of the Effectiveness of the Drug Cortexin in the Treatment of Neurological Disorders in Patients with Postcovid Syndrome. Results of the CORTEX Multicenter Clinical and Epidemiological Observational Program. Putilina MV; Mutovina ZY; Kurushina OV; Khalilova DM; Saverskaya EN; Stepanova SB; Khoreva MA; Starikov AS Neurosci Behav Physiol; 2022; 52(6):836-841. PubMed ID: 36311877 [No Abstract] [Full Text] [Related]
4. [Neurological disorders in the postcovid period]. Fedin AI Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(10):31-37. PubMed ID: 36279226 [TBL] [Abstract][Full Text] [Related]
5. [Neurological aspects of the consequences of COVID-19 in children]. Nemkova SA Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(4):23-30. PubMed ID: 35485061 [TBL] [Abstract][Full Text] [Related]
6. [Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX]. Putilina MV; Mutovina ZY; Kurushina OV; Khalilova DM; Saverskaya EN; Stepanova SB; Khoreva MA; Starikov AS Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):84-90. PubMed ID: 35175707 [TBL] [Abstract][Full Text] [Related]
7. Neurological Aspects of the Sequelae of COVID-19 in Children. Nemkova SA Neurosci Behav Physiol; 2022; 52(8):1169-1176. PubMed ID: 36817565 [TBL] [Abstract][Full Text] [Related]
8. [The result of prospective randomized study CITADEL - the efficacy and safety of drug cytoflavin in postcovid rehabilitation]. Putilina MV; Teplova NV; Bairova KI; Petrikeeva AE; Shabalina NI Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10):45-51. PubMed ID: 34874654 [TBL] [Abstract][Full Text] [Related]
9. Correction of Mitochondrial Dysfunction in the Complex Rehabilitation of COVID-19 Patients. Tereshin AE; Kiryanova VV; Reshetnik DA Neurosci Behav Physiol; 2022; 52(4):511-514. PubMed ID: 35892008 [No Abstract] [Full Text] [Related]
10. [Results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia]. Abramenko YV Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3. Vyp. 2):59-64. PubMed ID: 32307432 [TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia]. Kataeva NG; Zamoshchina TA; Svetlik MV Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(11):59-63. PubMed ID: 33340299 [TBL] [Abstract][Full Text] [Related]
12. [The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia]. Chukanova EI; Chukanova AS; Mamayeva KI Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(2):71-74. PubMed ID: 26081329 [TBL] [Abstract][Full Text] [Related]
13. [Postcovid cognitive impairment]. Shishkova VN; Dranitsina BG Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(12):45-49. PubMed ID: 36537630 [TBL] [Abstract][Full Text] [Related]
14. [Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia]. Zhuravleva MV; Kamchatnov PR; Vasyukova NS; Arkhipov VV; Kuznetsova EV; Kameneva TR; Serebrova SY Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11):29-39. PubMed ID: 36440774 [TBL] [Abstract][Full Text] [Related]
15. [Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19]. Kovalchuk VV; Ershova II; Molodovskaya NV Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(3. Vyp. 2):60-66. PubMed ID: 33908234 [TBL] [Abstract][Full Text] [Related]
16. [The efficacy of mexidol for transient ischemic attacks in the vertebrobasilar system in elderly patients with chronic cerebral ischemia]. Abramenko YV Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(9. Vyp. 2):42-48. PubMed ID: 30499559 [TBL] [Abstract][Full Text] [Related]
17. Postcovid Syndrome - The New Reality. Khoreva MA Neurosci Behav Physiol; 2022; 52(5):619-624. PubMed ID: 36119648 [TBL] [Abstract][Full Text] [Related]
18. [The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency]. Chukanova EI; Chukanova AS; Mamaeva KI Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(3):57-63. PubMed ID: 33834719 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO)]. Zakharov VV; Tkacheva ON; Mkhitaryan EA; Fedin AI Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):73-80. PubMed ID: 36412160 [TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia]. Shchepankevich LA; Nikolaev YA; Taneeva EV; Pervuninskaya MA; Shchepankevich MS Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10):32-37. PubMed ID: 34874652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]